Office of Commercialization and Economic Development
Office of Technology Commercialization

Protein: Chikungunya Virus Antigen,Full-Length

Technology #11-0063

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Mark Heise
Managed By
Tangible Property

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes outbreaks of debilitating acute and chronic arthralgia in humans. There are currently no approved vaccines and few therapies against CHIKV. This antigen preparation is derived from a full length molecular clone based on a contemporary clinical CHIKV isolate and can be used to generate diagnostic reagents against CHIKV. Inactivated whole virion CHIKV antigen has the potential to screen patient or animal serum for the presence of CHIKV specific antibodies, act as an antigen for generating CHIKV specific monoclonal antibodies, or produce an inactivated vaccine against CHIKV.

If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.

Related Publications: